Search Results

Most Favored Nation RESOURCES > MOST FAVORED NATION Most Favored Nation Policymakers continue to explore “Most Favored Nation” policies in a stated attempt to lower the cost of medicines. Unfortunately, these efforts do nothing to actually reduce costs for the millions of patients who rely on medicines to manage chronic diseases. Broader consideration of the consequences of these types of policies on patient access and innovation, as well as a more realistic focus on the real drivers of cost in the system, such as insurance practices and pharmacy benefit managers, must remain a priority. Trump’s ‘Most Favored Nation’ drug pricing push risks undermining pro-life legacy By Larry Bucshon, Michael Burgess April 22, 2026 Case Study: Cancer Treatment Delays New Case Study Highlights the Risk of Severe Treatment Delays for U.S. Patients Fighting Cancer Due to MFN GLOBE/GUARD: "What They Are Saying" Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the proposed GLOBE and GUARD prescription drug pricing models on patient access in America. Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the proposed GLOBE and GUARD prescription drug pricing models on patient access in America. Analysis: Patients Paid the Price New Analysis: Patients Paid the Price When Europe Controlled Drug Costs The QALY Paradox: An Unintended Consequence Of Most Favored Nation Drug Pricing By Dominique Seo, Kenneth E. Thorpe, T. Joseph Mattingly II February 18, 2026 MFN: "What They Are Saying" Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the “Most Favored Nation” pricing proposal on patient access in America. PBM Reform, Not MFN Why PBM Reform, not MFN, is a Viable Path to Affordable Drug Access Chronic Voices, Critical Choices YouTube Series To shed some light on concerns about the Most Favored Nation proposal and its impact on people living with chronic conditions, the Partnership to Fight Chronic Disease (PFCD) is hosting short discussions with health and policy experts to address challenges to patient access, discriminatory value metrics like the QALY, and threats to future innovation. PFCD's Vice President of Policy Candace DeMatteis and Alliance for Aging Research's Director of Public Policy and Government Relations Adina Lasser examine the “Most Favored Nation” drug pricing proposal and what it could mean for older Americans who rely on Medicare. They discuss the flaws of the quality-adjusted life year (QALY) and explore better policy solutions to lower drug costs without undermining innovation, access, or long-term health outcomes. PFCD's Vice President of Policy Candace DeMatteis and Global Colon Cancer Association CEO Andrew Spiegel dive into the real-world consequences of the federal government’s proposed “Most Favored Nation” (MFN) drug pricing model for cancer patients. They explore how importing foreign price controls could restrict access to cutting-edge treatments, slow innovation, and jeopardize the U.S. leadership in cancer research. In this conversation, PFCD ’s Ken Thorpe and Caregiver Action Network CEO Marvell Adams examine how “Most Favored Nation” drug pricing could reshape access to medicines for Medicaid beneficiaries. They discuss the potential ripple effects on caregivers, including added burdens from restricted access or disrupted care, and consider the broader equity implications for vulnerable populations. The discussion also explores practical policy alternatives that protect affordability while preserving innovation and reliable access to lifesaving treatments. Hear what National Organization for Rare Diseases CEO Pam Gavin has to say about the impacts of adopting "Most Favored Nation" and foreign reference pricing on people's access to lifesaving therapies for rare disease. Listen to what former Congressman Larry Bucshon, MD thinks as he sheds light on concerns about the proposal and its impact on people living with chronic conditions, particularly related to patient access, discriminatory value metrics like the QALY, and threats to future innovation. PFCD Statements and Comment Letters December 19, 2025 The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare and Medicaid Services (CMS) announcement of mandatory demonstration projects that would implement Most Favored Nation (MFN) drug pricing in Medicare Parts B and D. August 1, 2025 The Partnership to Fight Chronic Disease (PFCD) issued the following statement in response to President Trump’s most recent efforts to impose “Most Favored Nation” (MFN) drug pricing, which poses considerable risks to patient access, particularly to people living with one or more chronic diseases. May 12, 2025 The Partnership to Fight Chronic Disease (PFCD) issued the following statement in strong opposition to President Donald Trump’s "Most Favored Nation" (MFN) executive order, which aims to tie prescription drug prices in the U.S. to those in foreign countries May 5, 2025 The Partnership to Fight Chronic Disease (PFCD) today called on Congressional leaders and the Trump Administration to ensure that treatment access for people living with chronic diseases in Medicaid remains a priority across new policies that aim to make America healthy now and in the future.

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease What They Are Saying About "Most Favored Nation" Since 2007, the Partnership to Fight Chronic Disease (PFCD) has been an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease. The Problem: Preventable and Mismanaged Chronic Disease Chronic diseases, such as diabetes, COPD, cancer, depression, obesity and heart disease, are the leading causes of death and disability in the United States and account for the vast majority of health care spending. More than one in two American adults lives with at least one chronic condition and nearly one in three live with two or more chronic conditions. Chronic diseases are also the primary driver of health care costs—accounting for 90 cents of every dollar we spend on health care in this country. In 2011, this amounted to $2.3 trillion of the $2.7 trillion spent on health care. Despite these widespread problems, the issue of chronic disease does not register with large segments of the public and policymakers as an issue of primary concern. The Solution: A National Partnership Aimed at Fighting Chronic Disease As the CDC has said, “The United States cannot effectively address escalating health care costs without addressing the problem of chronic diseases.” Added to that, the World Health Organization estimates that as much as 80 percent of premature heart disease, stroke, and type 2 diabetes, and 40 percent of cancers could be avoided entirely if Americans avoided tobacco, developed healthier eating habits, and were more physically active. That’s why a broad group of patient, provider, community, business and labor groups, and health policy experts, joined together to form the Partnership to Fight Chronic Disease (PFCD)—a coalition committed to raising awareness of the rising rates of preventable and treatable chronic diseases. Our Mission: Rising rates of chronic diseases pose an unsustainable burden on our health care system. The viability and strength of the system—now and in the future—rely on a willingness to enact policies that help Americans better prevent and manage chronic illnesses. As a result, the mission of the PFCD is to: Drive awareness of burden of chronic disease and solutions at work shown to improve health for individuals and communities Empower change in how we prevent and treat chronic disease in America to enhance health Challenge decision-makers to adopt policy changes necessary to prevent and lessen burden of chronic disease

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease Resources RESOURCES > ARTHRITIS Arthritis According to the Arthritis Foundation, more than 50 million Americans have arthritis, making it the number one cause of disability in the country. With 1 in every 5 adults, and 300,000 children impacted by arthritis, there is also a high likelihood that many struggling with arthritis are also dealing with one or more other chronic conditions. Osteoarthritis and rheumatoid arthritis alone cost more than $156 billion a year in direct and indirect expenses. Prevent Arthritis Like most chronic conditions, some forms of arthritis can be prevented, but also better managed in order to deter further damage and alleviate symptoms. Healthy lifestyle choices like exercise and a balanced diet can help maintain strength and protect joints. Additionally, taking medicines as directed and prioritizing regular visits to your health care provider can help to address and reduce symptoms. Arthritis causes work limitations for 40 percent of the people with the disease and limits the daily activities of 21 million Americans; these limitations can be avoided with the right treatment. STUDY Gout Economic Impact Study

April 17, 2026 (Washington, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to recent analyses related to Alzheimer’s disease. “The recent review of anti-amyloid Alzheimer’s therapies highlights the complexity of measuring progress against a devastating disease, but its conclusions should be viewed with important context. By combining older, unsuccessful therapies with newer treatments that have demonstrated the ability to slow cognitive decline, the analysis risks misrepresenting meaningful advances and diminishing what these medicines can offer patients and families today. “For those living with Alzheimer’s and related dementias, even modest slowing of disease progression, such as the reductions in decline observed in recent trials, can translate into more time with loved ones, greater independence, and a critical window for future breakthroughs. Dismissing these gains because they are not cures overlooks what matters most to patients and caregivers. “At a time when the burden of Alzheimer’s continues to grow, the answer is not to step back from innovation, but to build on it, advancing a range of scientific approaches, improving how we measure meaningful outcomes, and ensuring patients have access to emerging therapies. The Partnership to Fight Chronic Disease remains committed to supporting continued research, thoughtful evaluation of evidence, and policies that accelerate progress for the millions of Americans affected by this disease.” ###

Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient impact, the independent think tank called Europe a "cautionary tale" for the U.S., particularly as the Trump administration continues to champion the expansion of price controls through “Most Favored Nation” (MFN) drug pricing policies. Patient wait times for treatment availability, as measured from regulatory approval to payer coverage, were slower in 25 of the 27 EU nations compared to the U.S. from 2014 to 2022, according to IQVIA. The Galen Institute found that, of 290 new medicines introduced globally between 2011 and 2018, 89% were available in the U.S. compared with only 62% in Germany, 48% in France and Switzerland, and 40% in Ireland. The data were starker for oncology medicines: 96% were available to American patients compared with 73% in Germany, 66% in France, 62% in Switzerland and 51% in Ireland. The report also traced the erosion of the pipelines that deliver patients new therapies. Between 1960 and 1965, European firms produced 65% of all new medicines worldwide. By 2004, that share collapsed to 18% while the U.S. share climbed to 62%. ITIF cited research by University of Southern California health economist Darius Lakdawalla and his colleagues, who found that lowering U.S. drug prices to European levels would reduce life expectancy for adults ages 55 to 59 by roughly two-tenths of a year. That amounts to more than four million life-years lost across that age group alone. For the more than 194 million Americans living with multiple chronic conditions, the analysis of Europe's decline hits close to home. These patients depend on a steady flow of new therapies to manage illness, preserve quality of life and survive. As a recent Partnership to Fight Chronic Disease study explored, chronic conditions are the primary driver  of rising health care spending across Medicare, Medicaid and private insurance, and obesity is a primary culprit. Adding longer wait times for new treatments to an already strained U.S. health care system would delay care, worsen patient outcomes and drive costs higher. The risk is too great. Ultimately, ITIF's analysis is a patient story. Europe's experience shows what happens when governments suppress the returns that fuel innovation. Americans with chronic disease cannot afford for history to be repeated. The full report from ITIF can be found HERE .

For millions of Americans living with cancer, access to innovative treatments is urgent and often lifesaving. The U.S. has long led the world in developing cutting-edge therapies, giving patients earlier access to new medicines and contributing to improved survival rates and quality of life. With 345 cancer medicines launched over a twelve-year span compared to just 191 in the U.K., a difference that translates directly into more treatment options and better outcomes for patients, it is clear that preserving that leadership must remain a top priority for policymakers. A new case study  demonstrates how patients with cancer in the U.K. have waited years, sometimes more than a decade, for access to a blood cancer medicine that is widely available in the U.S. This stark contrast highlights how price control policies, such as the Trump administration’s Most Favored Nation (MFN) proposals, which would tie U.S. drug prices to those set by foreign governments, risk undermining the very system that facilitates robust access to the latest treatments available to Americans today. Countries that rely on government-mandated price setting, like the U.K., utilize cost-effectiveness frameworks, such as the quality-adjusted life year (QALY), that systematically serve to delay or deny access to treatments by an arbitrary, and arguably unethical, measure. In this new series of case studies, the Partnership to Fight Chronic Disease will demonstrate how importing such pricing frameworks into the U.S. risks importing those same barriers for American patients and families navigating complex diagnoses. For people living with cancer and other chronic conditions, delays in access and fewer treatment options can have a devastating impact. Learn more about the unintended consequences of MFN at fightchronicdisease.org/MFN .